Compare MBBC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | BMEA |
|---|---|---|
| Founded | 1902 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 42.4M |
| IPO Year | 2020 | 2021 |
| Metric | MBBC | BMEA |
|---|---|---|
| Price | $14.94 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.17 |
| AVG Volume (30 Days) | 1.4K | ★ 1.5M |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3200.00 | 69.19 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $93.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.02 | $0.54 |
| 52 Week High | $15.79 | $2.24 |
| Indicator | MBBC | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 33.30 |
| Support Level | $14.58 | $0.55 |
| Resistance Level | $15.39 | $0.69 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 100.00 | 31.10 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.